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Abstract: Patients with multiple sclerosis (MS) are treated with drugs that may impact immune 
responses to SARS-CoV-2 vaccination. Evaluation of “prime-boost” (heterologous) vaccination reg-
imens including a first administration of a viral vector-based vaccine and a second one of an mRNA-
based vaccine in such patients has not yet been completed. Here, we present the anti-spike protein 
S humoral response, including the neutralizing antibody response, in a 54-year-old MS patient who 
had been treated with teriflunomide for the past 2 years and who received a heterologous ChAdOx1 
nCoV-19/BNT162b2 vaccination regimen. The results showed a very strong anti-S IgG response and 
a good neutralizing antibody response. These results show that teriflunomide did not prevent the 
development of a satisfactory humoral response in this MS patient after vaccination with a ChA-
dOx1 nCoV-19/BNT162b2 prime-boost protocol. 




Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
is recommended for all patients with multiple sclerosis (MS) [1]. However, MS-disease 
modifying therapies (MS-DMTs), which act on the immune system and modify humoral 
and cellular immune responses , can have an impact on vaccine responses [2]. A literature 
review published in September 2020, which focused on humoral responses induced by 
vaccines other than those against SARS-CoV-2 infection, showed that vaccine responses 
among MS patients receiving DMT varied depending on the vaccine, the situation 
(booster or new antigen) and the type of MS treatment [3]. Indeed, vaccine responses were 
reported to be reduced by varying degrees in patients treated with glatiramer acetate, 
teriflunomide, fingolimod or natalizumab, and a significant reduction in response was 
observed in patients under anti-CD20 treatment (Ocrelizumab, Rituximab), in particular 
towards new antigens. However, few studies providing quantitative and qualitative 
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evaluations of humoral responses in patients treated with MS-DMT have been published 
so far. A first case of vaccine failure in an MS patient receiving MS-DMT has been re-
ported, with a patient on ocrelizumab showing an absence of postvaccination seroconver-
sion and the development of a SARS-CoV-2 infection 19 days after a second dose of the 
mRNA BNT162b2 vaccine [4]. Two studies evaluating humoral responses to vaccination 
with a mRNA BNT162b2 vaccine or ChAdOx1 nCoV-19 in MS patients, either treated with 
MS-DMT or untreated, found that the titer of anti-SARS-CoV-2 spike protein IgG was 
lower in anti-CD20 and S1PR modulator compared to untreated patients or patients re-
ceiving other MS-DMT [5,6]. No specific data on teriflunomide were reported in these 
studies. 
The postvaccination thrombosis has occurred in some patients aged < 55 years who 
had received one of the adenoviral vector SARS-CoV-2 vaccines. This led French authori-
ties to modify the vaccination regimen in people aged < 55 years [7]. For those who had 
received a first dose of the ChAdOx1 nCoV-19 vaccine, the second dose of the ChAdOx1 
nCoV-19 vaccine should be replaced by a dose of an mRNA vaccine, such as the BNT162b2 
vaccine, while respecting the planned time interval between doses [8]. Evaluation of this 
“prime-boost” or heterologous vaccination regimen, has not yet been completed [9].  
Here, we present an evaluation of the humoral response to SARS-CoV-2 vaccination, 
including assessment of the neutralizing antibody response, in a 54-year-old MS patient 
who had been treated with teriflunomide for the past 2 years and who received a heterol-
ogous vaccination regimen. 
2. Case Description 
The patient was a 54-year-old woman who began treatment with glatiramer acetate 
in 2003 and then switched treatment with teriflunomide (1 tablet/day) in July 2019. Pre-
scription renewal data indicate that the patient showed good medication adherence. She 
received a first-dose SARS-CoV-2 vaccine (ChAdOx1 nCoV-19) on 13 March 2021 and a 
second-dose SARS-CoV-2 vaccine (mRNA BNT162b2) on 12 May 2021, i.e., almost 9 weeks 
after the first dose. 
Humoral response induced by vaccination with a heterologous protocol (ChAdOx1 
nCoV-19 /mRNA BNT162b2)  
Two sets of four serological tests were performed: the LIAISON® SARS-CoV-2 Tri-
meric S IgG assay (DiaSorin, Saluggia Italy) and the Architect® anti-spike test (Abbott, 
Rungis France), both directed against the SARS-CoV-2 S-protein; the iFlash®-2019-nCoV 
NAb (Orgentec®, Trappes France) assay to measure SARS-CoV-2 neutralization antibody 
levels, and the Architect® anti-N SARS-CoV-2 IgG assay (Abbott, Rungis France) to assess 
a potential previous natural infection [10–12]. The first set of tests was performed 14 and 
28 days after administration of the second dose of the vaccine (Table 1). The results 
showed a strong anti-S antibody response (>40,000 and >40,000 AU/mL at day14 and 28 
post second vaccination, respectively) and a good neutralizing antibody response.  
Table 1. Humoral response in a patient treated with teriflunomide and vaccinated with a heterolo-
gous protocol (ChAdOx1 nCoV-19-mRNA BNT162b2). 
Test 
Antibody Titers (AU/mL) after a Heterologous Vaccination 
Regimen: 
ChAdOx1 nCoV-19-mRNA BNT162b2 
D14 post-2nd vaccination D28 post-2nd vaccination 
LIAISON® SARS-CoV-2 
TrimericS IgG assay 
(DiaSorin®; threshold: 13 
AU/mL) [10] 
>800 >800 
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Architect® anti-spike test 









CoV-2 IgG assay (Abbott) 
Negative Negative 
AU: arbitrary unit 
3. Discussion 
Both types of vaccine received by the patient described in our report encode the same 
antigen, i.e., the S protein of the first SARS-CoV-2 strain. The ChAdOx1 nCoV-19 vaccine 
is a non replicative recombinant viral-vectored vaccine; the replication-deficient simian 
adenovirus vector (ChAdOx1) contains the full-length S protein expressed in its trimeric 
prefusion conformation [13,14]. The mRNA BNT162b2 vaccine also encodes the full-
length S protein, but in this vaccine the protein is stabilized in the prefusion conformation 
by proline substitutions at residues 986 and 987 [15]. Previous studies have shown that 
heterologous vaccination regimens, in which the same antigen (Plasmodium falciparum or 
Influenza A) is administered by different viral vectors in order to avoid the antivector 
memory response, can induce satisfactory immune responses [16,17]. Indeed, this strategy 
is currently being used for the Gam-COVID-Vac vaccine, where two different adenovirus 
serotypes (26 and 5) are being used in the prime and booster doses [18].However, the 
prime-boost regimen used in our patient differed significantly from that used for the Gam-
COVID-Vac vaccine in that the boost in our case was achieved with an mRNA vaccine 
instead of a vaccine using another viral vector. Unexpectedly, the anti-S IgG response ob-
served after the booster dose was very high (>40,000 AU/mL from day 14 after the second 
dose) and much greater than those we observed previously in nonimmune-suppressed 
subjects vaccinated with homologous vaccination regimens, including either two doses of 
the ChAdOx1 nCoV-19 or two doses of mRNA BNT162b2 vaccines (data not shown). Teri-
flunomide selectively and reversibly inhibits dihydroorotate dehydrogenase, a key en-
zyme in the de novo synthesis of pyrimidine and has a cytostatic effect on proliferating T- 
and B-lymphocytes. Teriflunomide may, therefore, have inhibited, at least partly, the anti-
vector response in our patient, and thus may have allowed prolonged antigen expression. 
As reported by Geiben-Lynn et al. for rAd5 transgene expression in nude mice, this pro-
longed antigen expression would likely have been beneficial for B-cell priming [19]. The 
authors reported that vaccine antigen clearance is mostly dependent on the strength of 
adaptive immune responses, and that these responses are associated with the strength of 
the elicited memory cellular responses, with T lymphocytes playing a central role in 
damping rAd5 transgene expression. Thus, prolonged expression of the Sprotein after the 
priming dose may have compensated for the immunosuppressive effect of teriflunomide 
on the anti-S T cell immune response, and consequently on the memory B cell response. 
Using an mRNA-based vaccine for the booster dose in SARS-CoV-2 regimens may there-
fore allow the problem of neutralizing anti-vector antibodies to be avoided, potentially 
making the vaccines more effective. Another unexpected finding from our study was that 
the strong total anti-S antibody response was not associated with a strong neutralizing 
antibody titer, as it was similar to that observed in our experience for the non immuno-
suppressed subjects mentioned above. These results highlight the complexity of evaluat-
ing qualitative humoral responses at the individual level. However, the very high titer of 
anti-S IgG observed in our MS patient, together with the neutralizing antibody titer simi-
lar to that observed in subjects without immunosuppressive therapy after two doses of 
ChAdOx1 nCoV-19 or mRNA BNT162b2 vaccines, show that teriflunomide may not 
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prevent a quality humoral anti-SARS-CoV-2 response. As the neutralizing antibodies’ titer 
during the peri-infection period has been recently correlated with protection, it can be 
assumed that our patient is as protected as the non immunosuppressed subjects who re-
ceived homologous protocols [20].  
4. Conclusions 
Although the case presented did not allow any correlations to be made between se-
rological findings and the level of protection afforded by SARS-CoV-2 vaccines in DMT-
treated MS patients, the case presented here shows that teriflunomide did not prevent the 
development of a satisfactory humoral response in an MS patient who received a prime-
boost ChAdOx1 nCoV-19/m RNA BNT162b2 heterologous vaccination regimen. 
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